The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
|Articles|February 5, 2007
Democrats reopen debate on Medicare Part D
The Democrats opened a new salvo in the battle over the Medicare drug benefit with the introduction of the Medicare Prescription Drug Price Negotiation Act of 2007. The bill, which passed the House mostly along party lines, mandates that the Secretary of the Department of Health & Human Services (DHHS) negotiate directly with drug companies over drug prices charged to prescription drug plans (PDPs). Still, the bill's future and how it will impact pharmacy remains unclear.
Advertisement
Advertisement
Related to this article
The Milken Institute released survey results alongside new data regarding the need for pharmacists in extending effective GLP-1 care.
Through the ACCESS program, Mark Ey, RPh, notes that pharmacies can now start billing for a variety of services they’ve already been providing.
The medication significantly increased risk of pregnancy loss when compared with macrolide antibiotics, amoxicillin, and topical clindamycin for acne.
In part 3, Rebold explores improving the ART formulary protocol through introducing pharmacist-led transition-of-care services.
Our hosts explore why ketone monitoring matters, what pharmacists should know about Libre Duo, and how patient education can support proactive care management.
Mark Ey, RPh, details the patient-focused factors of the ACCESS to Pharmacy Care Program and the ways in which valued care translates to reimbursement.
A new option for adults who have experienced stroke will now be available to further reduce future risk.
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Adds NAION Eye Risk Warning to All GLP-1 Labels
2
New Report Finds Pharmacies Key in Long-Term GLP-1 Success
3
The Pharmacy Model Creating New Billing Pathways, Improved Recognition
4
Vaxcyte’s VAX-31 Pneumococcal Vaccine Meets All Phase 3 Primary Goals
5